-
Mashup Score: 6
Purpose Children have historically been excluded from first-in-human studies of promising new cancer drugs and later phase adult clinical trials. Delays in evaluation may result in off-label use without dosing information as the only access to new drugs. A multistakeholder workshop was convened in May 2016 by ASCO and Friends of Cancer Research to identify opportunities for when it would be scientifically appropriate to expand trial eligibility to include children younger than age 18 years in first-in-human and other adult cancer clinical trials. Methods This group convened experts from academia, government, and industry to review barriers to enrolling children and adolescents in oncology clinical trials. We evaluated the historical context, published literature, regulatory considerations, and myriad risks and benefits associated with lowering the age of enrollment on oncology clinical trials. Results We conclude that many of the historical concerns about including children early in on
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 22Prior Authorization and Association With Delayed or Discontinued Prescription Fills - PubMed - 5 month(s) ago
Introduction of a new prior authorization policy on an established drug regimen is associated with increased probability of discontinued and delayed care. For some conditions, this may represent a clinically consequential barrier to access. Waiving prior authorization for patients already establishe …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists1Tweet-
Important data on impact of prior auth on pts with cancer: New prior auth requirements on established anti cancer drugs: ⬆️ drug discontinuation within 120 days (adjusted OR 7.1; P < .001) ⬆️time to next fill by 9.7 days; P < .001) This is not okay! https://t.co/7AlMiyA7Tc
-
-
Mashup Score: 20Prior Authorization and Association With Delayed or Discontinued Prescription Fills - PubMed - 5 month(s) ago
Introduction of a new prior authorization policy on an established drug regimen is associated with increased probability of discontinued and delayed care. For some conditions, this may represent a clinically consequential barrier to access. Waiving prior authorization for patients already establishe …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Oncologists1Tweet-
Important data on impact of prior auth on pts with cancer: New prior auth requirements on established anti cancer drugs: ⬆️ drug discontinuation within 120 days (adjusted OR 7.1; P < .001) ⬆️time to next fill by 9.7 days; P < .001) This is not okay! https://t.co/7AlMiyA7Tc
-
-
Mashup Score: 6
Communications Chemistry – Gas chromatography is a useful tool to identify and characterize wines, usually by selecting some compounds for a particular classification problem, yet, with limited…
Source: www.nature.comCategories: General Medicine News, Oncologists1Tweet-
And a link to the publication for those who want to delve into the methods 🙂 Predicting Bordeaux red wine origins and vintages from raw gas chromatograms | Communications Chemistry https://t.co/95MZcPSaI7
-
-
Mashup Score: 13Bordeaux Wine Snobs Have a Point, According to This Computer Model - 5 month(s) ago
With machine learning, scientists are trying to chemically define the murky concept of terroir. The models might be useful for detecting wine fraud.
Source: www.nytimes.comCategories: General Medicine News, Oncologists1Tweet-
If you want to learn more about machine learning (ML) but need a break from oncology… -What happens when ML methods are applied to GC profiles of wine? 🍷 ➡️ Wines from the same estate cluster together (ie terroir is ‘real’) ➡️ Vintages are distinct https://t.co/Mtygmz1U8Y
-
-
Mashup Score: 150Conquer Cancer announces 2023 Advanced Clinical Research Award in Triple Negative Breast Cancer Research Recipient | Conquer Cancer, the ASCO Foundation - 6 month(s) ago
ALEXANDRIA, Va. — Conquer Cancer®, the ASCO Foundation, is pleased to award Ana Garrido-Cast ro, MD, with the 2023 Conquer Cancer – Triple Negative Breast Cancer Foundation Advanced Clinical Research Award (ACRA), for her research project “Unraveling mechanisms of resistance to antibody drug conjugates in triple-negative breast cancer.” The development of resistance to standard therapies represents a significant challenge in the treatment of metastatic triple-negative breast cancer (mTNBC). Novel
Source: www.conquer.orgCategories: General Medicine News, Oncologists1Tweet-
Congratulations to Dr. Ana Garrido-Castro for being selected as a recipient of an ASCO ACRA award for her research on ADC sequencing and resistance in TNBC!!! ❤️🎉😊 https://t.co/mTq91nDdUd https://t.co/4sEqnkg2kS
-
-
Mashup Score: 6Metastatic Breast Cancer Support and Education - Dana-Farber Cancer Institute | Boston, MA - 7 month(s) ago
One of the goals of the Ending Metastatic Breast Cancer for Everyone (EMBRACE) program is to provide resources and information to help guide patients through many situations and decisions. Throughout their journey, metastatic breast cancer patients in the EMBRACE program receive education and support from expert clinicians, other professionals, and one another.
Source: www.dana-farber.orgCategories: Latest Headlines, Oncologists1Tweet-
Excited to kick off our annual virtual #EMBRACE #MBC forum for patients and loved ones on October 28! Registration is free. https://t.co/9EUAneN9GF https://t.co/MwhlQkjr9Y
-
-
Mashup Score: 0
Internal documents and former company executives reveal how Cigna doctors reject patients’ claims without opening their files. “We literally click and submit,” one former company doctor said.
Source: ProPublicaCategories: Latest Headlines, Oncologists1Tweet-
Infuriating and explains so much. Refutes the oft-repeated claim that insurers do thorough “medical review” primarily to “protect patients.” https://t.co/GFwBe76s8D
-
-
Mashup Score: 2Couple commits $2 million to fund groundbreaking clinical trials. - The Dana-Farber Campaign - 1 year(s) ago
Langley Perer and Scott Rosenberg have made a substantial $2 million commitment for LBM research at Dana-Farber Cancer Institute.
Source: The Dana-Farber CampaignCategories: Latest Headlines, Oncologists1Tweet-
Langley is a remarkable person and I am privileged to be working with her. With the support of Langley and her husband, we are working hard to launch new clinical trials for people living with leptomeningeal disease. https://t.co/VBSTmQxMoV https://t.co/CmpEWbtSbd
-
-
Mashup Score: 1Ask Your Members of Congress to Cosponsor the Metastatic Breast Cancer Access to Care Act - 2 year(s) ago
Ask your representative to support the Metastatic Breast Cancer Access to Care Act, so anyone living with metastatic breast cancer doesn’t have to wait for the treatments they need. The time to take action is now! [@campaign] #KomenAdvocacy
Source: Susan G. KomenCategories: Latest Headlines, Oncologists1Tweet-
Today, on National Metastatic Breast Cancer Awareness Day, please ask your representative to support the MBC Access to Care Act. It will take less than 5 min of your time - click on the link for more details. https://t.co/Nc8rsXVphi https://t.co/k8Vrhynnh7
-
@tmprowell @NIH @NIHDirector If it is possible to lower the minimum age in oncology trials it should be possible in long Covid trials! https://t.co/ytPocYcksJ